High Prolyl 4-Hydroxylase Subunit Alpha 3 Expression as an Independent Prognostic Biomarker and Correlated With Immune Infiltration in Gastric Cancer

Xiaoji Niu1,2, Liman Ren3, Shoumei Wang2, Dong Gao1, Mingyue Ma2, Aiyan Hu2, Hongjun Qi1* and Shuhui Zhang2*

1Department of Gastroenterology of Traditional Chinese Medicine, Qinghai Province Hospital of Traditional Chinese Medicine, Xining, China; 2Department of Pathology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China; 3Department of Endocrinology, Qinghai Province Hospital of Traditional Chinese Medicine, Xining, China

Background: Gastric cancer (GC) has a high mortality rate and is particularly prevalent in China. The extracellular matrix protein, prolyl 4-hydroxylase subunit alpha 3 (P4HA3), has been implicated in various cancers. We aimed to assess the diagnostic and prognostic value of P4HA3 in GC and investigate its correlation with immune cell infiltration.

Methods: The present study used microarray data from the Cancer Genome Atlas (TCGA) to analyze the association of P4HA3 expression with clinicopathological features. Data from the Gene Expression Omnibus (GEO) were used for validation. Receiver operating characteristic (ROC) and Kaplan–Meier curves were constructed to determine the diagnostic and prognostic value of P4HA3 in GC. Univariate and multivariate regression analyses were performed to assess the impact of P4HA3 on overall survival (OS) rates. A protein–protein interaction (PPI) network was generated and functional enrichment evaluated. Single-sample gene set enrichment analysis (ssGSEA) was conducted to correlate P4HA3 expression with immune cell infiltration. The correlation between P4HA3 and immune check point genes was studied.

Results: P4HA3 was over-expressed in GC, along with 15 other types of cancer, including breast invasive carcinoma and cholangiocarcinoma. P4HA3 showed high diagnostic and prognostic value in GC and was an independent prognostic factor. P4HA3, TNM (tumor, node, metastases) stage, pathological stage and age all correlated with OS rates. Genes related to P4HA3 were enriched in the lumen of the endoplasmic reticulum and included procollagen-proline 3-dioxygenase activity. P4HA3 expression correlated with numbers of macrophages, natural killer (NK) cells, immature dendritic cells (iDC), mast cells, eosinophils, effective memory T cells (Tem), T-helper 1 (Th1) cells and dendritic cells (DC). P4HA3 was positively correlated with hepatitis A virus cellular receptor 2 (HAVCR2) and programmed cell death 1 ligand 2 (PDCD1LG2).
INTRODUCTION

Data from Global Cancer Statistics (https://gco.iarc.fr/today/online-analysis) indicates that gastric cancer (GC) is the fifth most frequently diagnosed cancer and the fourth leading cause of cancer-related death worldwide. Global age-standardized incidence and mortality rates are 11.1 per 100,000 and 7.7 per 100,000. Rates are considerably higher in China, where incidence and mortality occur at 20.6 per 100,000 and 15.9 per 100,000, respectively (Machlowska et al., 2020; Sung et al., 2021; Niu et al., 2022). GC is thus a significant health and economic burden worldwide and this is particularly the case in China.

The majority of GC cases are diagnosed at the late stage, resulting in a poor prognosis. However, advances in molecular biology techniques allow us to approach a better understanding of precise molecular mechanisms of carcinogenesis which holds promise for development of diagnostic, prognostic and therapeutic strategies. It is known that immune-related mechanisms and markers participate in the occurrence and development of GC and appropriately targeted therapy looks promising for its treatment (Güthle et al., 2020). Such observations highlight the urgent need to identify new immune-related biomarkers to facilitate early GC diagnosis and treatment.

Prolyl 4-hydroxylase subunit alpha 3 (P4HA3) is a catalytic subunit involved in collagen synthesis. Its overexpression has been associated with tumors and with non-cancerous diseases, including idiopathic pituitary adenoma, melanoma, stomach carcinoma, breast cancer and pulmonary fibrosis (Luo et al., 2015; Song et al., 2018; Atkinson et al., 2019; Long et al., 2019; Gu et al., 2020).

A recent study has suggested that upregulation of P4HA3 is associated with enhanced metastasis and poor survival of GC patients (Song et al., 2018). However, any correlation with immune cell infiltration has been little scrutinized. The current study investigated P4HA3 expression in GC and its relationship with immune cell infiltration.

MATERIAL AND METHODS

Microarray Datasets

The Cancer Genome Atlas (TCGA) project (https://www.cancer.gov/tcga) is an open database which aims to make molecular data characterizing the cancer-related genome freely available and to link genomic data to patients’ clinicopathological information. RNA-sequencing data (level 3) with corresponding clinicopathological information were downloaded from the TCGA database. Data was converted from fragments per kilobase per million (FPKM) to transcripts per million reads (TPM). Survival data were published in Cell (Liu et al., 2018). For analyses across many tumor types, TCGA and Genotype-Tissue Expression Project (GTEx), TPM-formatted RNAseq data processed by Toil were downloaded from University of California Santa Cruz (UCSC) XENA (https://xenabrowser.net/datapages/) (Vivian et al., 2017). GSE54129 and GSE103236 datasets were obtained from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) to validate the P4HA3 expression level. Table 1 shows the details of expression datasets involved in the study.

| Table 1 | Details of Expression Datasets for the study. |
|---------|---------------------------------------------|
| Data source | ID | Platform | Samples (cancer vs. Normal) |
| TCGA | - | - | 375 vs. 32 |
| GEO | GSE54129 | GPL570 | 111 vs. 21 |
| GEO | GSE103236 | GPL4133 | 10 vs. 9 |

Diagnostic and Prognostic Value of P4HA3

Receiver operating characteristic (ROC) and Kaplan-Meier survival curves were constructed and used to analyze the diagnostic and prognostic value of P4HA3, respectively. The association between P4HA3 expression and overall survival (OS) rates of GC patients was assessed by univariate and multivariate regression analyses.

PPI Network Construction and Functional Enrichment Analysis

Protein–protein interaction (PPI) network analysis of P4HA3 was performed by using the search tool of a single named protein with default parameters within the STRING database (version 11.5, accessed date: 02 June 2022) (Szklarczyk et al., 2021). Pathway and process enrichment analysis were conducted with the following ontology sources: Gene Ontology (GO) Biological Processes, GO Cellular Components, GO Molecular Functions, Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway, Reactome Gene Sets and Canonical Pathways within the Metascape database (https://metascape.org/gp/index.html) (Hochberg and Benjamini, 1990; Zhou et al., 2019). The complete proteome were regarded as the background to enrichment. Terms with a p-value less than 0.05, a minimum count of 3 and an enrichment factor (ratio of observed counts: counts expected by chance) of more than 1.5 were acquired and grouped into clusters based on their connections. p-values were calculated from the cumulative hypergeometric distribution and q-values using the Banjamini-Hochberg procedure to account for multiple testing. Kappa scores were used as the similarity metric when performing hierarchical clustering of the enriched terms and sub-trees with a similarity of >0.3 were considered a cluster. The most statistically significant term within a cluster was used to represent that cluster.

Conclusion: P4HA3 is a potential independent biomarker for prognosis of GC and may be an immunotherapy target in the treatment of GC.

Keywords: P4HA3, gastric cancer, bioinformatics, prognosis, immune infiltration
Correlation Analysis of Immune Cell Infiltration

ssGSEA was used to determine relationships between P4HA3 expression and 24 kinds of immune cells, including activated DC, B cells, macrophages and mast cells (Bindea et al., 2013). Spearman correlation analysis was used to evaluate the correlation between P4HA3 and immune cell infiltration and values of $r > 0.3$ or $r < -0.3$ and $p < 0.05$ were considered to indicate significant positive or negative correlation. The expression of the following immune-checkpoint–relevant transcripts was assessed: sialic acid binding Ig like lectin 15 (SIGLEC15), T cell immunoreceptor with Ig and ITIM domains (TIGIT), CD274 Molecule (CD274), hepatitis A virus cellular receptor 2 (HAVCR2), programmed cell death 1 (PDCD1), cytotoxic T-lymphocyte associated protein 4 (CTLA4), lymphocyte activating 3 (LAG3) and programmed cell death 1 ligand 2 (PDCD1LG2) (Zeng et al., 2019).

Statistical Analysis

All the analytical methods (excluding functional enrichment analysis) were performed using Xiantao Academic (https://www.xiantao.love/products) embedded with R software and R packages, including org.Hs.eg.db, GEOquery, limma, ggplot2, clusterProfiler, survminer, survival and pROC (Davis and Meltzer, 2007; Yu et al., 2012; Liu et al., 2018; Hu et al., 2020). Chi-square test, paired t test and the Wilcoxon rank sum test were used to compare data. A value of $p$ value < 0.05 was regarded as statistically significant.

RESULTS

Clinicopathological Characteristics

The flowchart of the present study is presented in Figure 1. RNA-seq expression data from 624 samples, including 174 normal tissues, 36 para carcinoma tissues and 414 tumor tissues plus clinical data were downloaded from UCSC XENA. The details are presented in Table 2.
**Expression of P4HA3 Across Many Cancer Cell-Types**

Differential expression of P4HA3 mRNA was measured and found to be over-expressed in 16 cancers, including breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), acute myeloid leukemia (LAML), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), rectum adenocarcinoma (READ), thymoma (THYM) and stomach adenocarcinoma (STAD; **Figure 2A**). All-sample and paired-sample analysis showed that expression levels of P4HA3 were higher in GC tissue than in non-cancerous tissue (**Figures 2B,C**). Further analysis using GSE54129 (**Figure 2D**) and GSE103236 (**Figure 2E**) gave similar results to those from the TCGA data.

**P4HA3 Expression and GC Clinicopathological Features**

The correlation analysis showed significant differences for some clinicopathological features, including *Helicobacter pylori* infection status (**Figure 3A**), pathological stage (**Figure 3B**), T classification (**Figure 3C**) and histological grade (**Figure 3D**). There were no differences in P4HA3 expression based on gender (**Figure 3E**) or age (**Figure 3F**).

**Correlation Analysis of Prognosis**

The area under the ROC curve was 0.933, based on TCGA data (**Figure 4A**), and 0.874 for non-cancerous samples of GTEx combined para carcinoma tissues and GC samples (**Figure 4B**). These results indicate that levels of P4HA3 expression are consistently different in tumor and non-tumor tissues. Kaplan-Meier survival analysis indicated that high levels of P4HA3 are associated with poor prognosis (**Figure 4C**).

Univariate analysis demonstrated that high P4HA3 expression corresponded to reduced OS and, thus, poor prognosis for GC patients (**Table 3**). TNM stage, pathological stage and age were also associated with reduced OS (**Table 3**). The results of multivariate analysis showed that P4HA3 was an independent prognostic marker. TNM stage and age also had independent prognostic value for OS in GC (**Table 3**).

**PPI Networks and Enrichment Analysis**

The present study reports the construction of a network of P4HA3 and its related genes using the STRING database. P4HA3-related genes with scores above 0.9 included Collagen Type I Alpha (COL1A1), COL1A2, COL3A1, COL6A3, COL12A1, COL20A1, prolyl 3-hydroxylase (P3H)1, P3H2 and P3H3 (**Figure 5**; **Table 4**). Metascape pathway and process enrichment analysis revealed that all genes related to P4HA3 were enriched in R-HSA-1650814, suggesting roles in collagen biosynthesis and modifying enzymes. The endoplasmic reticulum lumen and procollagen-proline 3-dioxygenase activity were also associated with P4HA3 (**Table 5**).
Correlation Analysis of Immune Infiltration

The association between P4HA3 and the degree of immune cell infiltration in GC was explored using ssGSEA analysis (Figure 6A). Macrophages, NK cells, iDC, mast cells, eosinophils, Tem, Th1 cells and DC all correlated with P4HA3 (Figures 6B–I).

Patients were divided into two groups according to P4HA3 expression and those with high expression had higher levels of the immune-checkpoint–relevant transcripts, HAVCR2 and PDCD1LG2, than those with low expression (Figure 7A). P4HA3 expression was positively correlated with HAVCR2 (Figure 7B) and PDCD1LG2 (Figure 7C).

DISCUSSION

Prolyl 4-hydroxylase (P4H) activity is essential for maintenance of the collagen triple helix and P4HAs (P4HA1, P4HA2, P4HA3) plus P4HB are highly expressed in numerous tumors where they may contribute to cancer progression. A number of inhibitors of P4HAS and P4HB have been shown to exert anti-tumor effects, suggesting that P4H is an achievable target for cancer therapy (Shi et al., 2021). Expression profiles and functional roles of P4HA3 in GC have rarely been studied. The current study focused on the diagnostic, prognostic and potential immune therapeutic target value of P4HA3 in GC.

mRNA expression levels across many different cancer types were analyzed using data from the TCGA database. P4HA3 mRNA was up-regulated in GC, along with BRCA, CHOL, COAD, DLBC, ESCA, GBM, HNSC, KIRC, LAML, LUAD, LUSC, PAAD, PCPG, READ and THYM, in agreement with the previous study of Hu et al., 2020. P4HA3 up-regulation was confirmed using GSE54129 and GSE103236 from the GEO database.

A key component of the current study was to address the diagnostic and prognostic value of P4HA3. GC patients tended to have higher P4HA3 mRNA expression when they were infected by HP, resulting in diagnosis with higher T stages and lower histological grades, or when they were diagnosed at late pathological stages. ROC analysis indicated differences in P4HA3 expression between tumor tissues and non-cancerous tissues. Kaplan–Meier survival analysis indicated that those GC patients with higher levels of P4HA3 tended to have shorter OS. Multivariate Cox analysis demonstrated that high levels of P4HA3 mRNA constituted an independent risk factor for OS.
and were associated with poor GC prognosis. Thus, we believe that P4HA3 could serve as a novel diagnostic and independent prognostic biomarker for GC patients.

P4HA3 has been shown to have an association with many different cancers. It promoted cell proliferation, invasion and migration in head and neck squamous cell carcinoma and...
melanoma cells (Atkinson et al., 2019; Wang et al., 2020) and reduced the anti-tumor activity of COL6A6 on growth and metastasis of AtT-20 and HP75 melanoma cells due to an action on PI3K-Akt signaling (Long et al., 2019). P4HA3 is known to be upregulated in clear cell renal carcinoma and patients with higher expression had worse outcomes, indicating a prognostic role for P4HA3 (Liu et al., 2020).

Findings of the present and previous studies indicate that P4HA3 maintains the stability of newly synthesized collagens and remodels the extracellular matrix in GC (Shoulders and Raines, 2009; Gilkes et al., 2013, 2014). Macrophages and NK cells influence the tumor microenvironment and tumor immunity (Lee et al., 2014; Sammarco et al., 2019; Gambardella et al., 2020). Infiltration of M2 macrophages promotes tumor cell escape and thus, numbers may reflect prognosis (Liu X. et al., 2021). Infiltration of NK cells has an impact on immunotherapy and targeting NK cells may improve the anti-tumor immune response (Yang et al., 2019; Bi et al., 2021). P4HA3 expression correlated with immune infiltration by macrophages and NK cells.

Immune checkpoint molecules regulate self-tolerance to prevent autoimmune reactions and minimize tissue damage by controlling the length and intensity of the immune response. Expression of checkpoint molecules acts to limit the immune and anti-tumor immune response, enabling escape of tumor cells (Galluzzi et al., 2020; Liu Y. et al., 2021). Patients with higher P4HA3 mRNA expression tended to have higher expression of the immune checkpoint related genes, PDCD1LG2 and HAVCR2. The current findings indicate the potential for targeting of P4HA3 during GC immunotherapy.

In conclusion, the purpose of the current study was to determine the diagnostic and prognostic value of P4HA3 and its correlation with immune cell infiltration in GC. P4HA3 emerges as a feasible diagnostic and prognostic biomarker and immunotherapy target. However, the current results are all derived from bioinformatics analysis and limited by the absence of experimental confirmation. Further clinical experiments are underway to verify the function of P4HA3 in GC.

| Variable | Total (N) | Univariate analysis | Multivariate analysis |
|----------|-----------|---------------------|----------------------|
| T stage (T1 vs. T2&3&4) | 362 | 8.829 (1.234-63.151) | 0.030 | 3.735 (0.502-27.792) | 0.198 |
| N stage (N0 vs. N1&2&3) | 352 | 1.925 (1.264-2.931) | 0.002 | 1.365 (0.749-2.454) | 0.314 |
| M stage (M0 vs. M1) | 352 | 2.254 (1.295-3.924) | 0.004 | 1.969 (1.015-3.781) | 0.045 |
| Pathological stage (Stage I& II vs. III& IV) | 347 | 1.947 (1.358-2.793) | <0.001 | 1.371 (0.819-2.294) | 0.230 |
| Grade (G1&G2 vs. G3) | 361 | 1.353 (0.957-1.914) | 0.067 | 1.290 (0.878-1.894) | 0.194 |
| Age (≤65 vs. >65) | 367 | 1.620 (1.154-2.276) | 0.005 | 1.866 (1.278-2.725) | 0.001 |
| Gender (Female vs. Male) | 370 | 1.267 (0.891-1.804) | 0.188 | - | - |
| H pylori infection (NO vs. Yes) | 162 | 0.650 (0.279-1.513) | 0.317 | - | - |
| Reflux history (No vs. Yes) | 213 | 0.582 (0.291-1.162) | 0.125 | - | - |
| P4HA3 (Low vs. High) | 370 | 1.634 (1.169-2.284) | 0.004 | 1.641 (1.135-2.374) | 0.008 |

Notes: Bold type indicates statistical significance.
Abbreviations: P4HA3, Prolyl 4-hydroxylase subunit alpha 3; HR, hazard ratio; CI: confidence interval.

TABLE 4 | The detailed information of P4HA3-related genes.

| Gene symbol | Annotation | Score |
|-------------|------------|-------|
| COL1A1      | collagen type I alpha 1 chain | 0.951 |
| COL1A2      | collagen type I alpha 2 chain | 0.926 |
| COL3A1      | collagen type III alpha 1 chain | 0.933 |
| COL6A3      | collagen type VI alpha 3 chain | 0.927 |
| COL12A1     | collagen type XII alpha 1 chain | 0.927 |
| COL20A1     | collagen type XX alpha 1 chain | 0.941 |
| P3H1        | prolyl 3-hydroxylase 1 | 0.934 |
| P3H2        | prolyl 3-hydroxylase 2 | 0.989 |
| P3H3        | prolyl 3-hydroxylase 3 | 0.944 |
TABLE 5 | Clusters with their representative enriched terms (one per cluster).

| Term Category          | Description                                          | Count (%) | p      | q      |
|------------------------|------------------------------------------------------|-----------|--------|--------|
| R-HSA-1650814 Reactome Gene Sets | Collagen biosynthesis and modifying enzymes | 9 (100)   | <0.001 | <0.001 |
| M3005 Canonical Pathways | NABA COLLAGENS | 6 (66.67) | <0.001 | <0.001 |
| GO:0005788 GO Cellular Components | endoplasmic reticulum lumen | 8 (88.89) | <0.001 | <0.001 |
| GO:0019797 GO Molecular Functions | procollagen-proline 3-dioxygenase activity | 3 (33.33) | <0.001 | <0.001 |

Abbreviation: GO, gene ontology.

FIGURE 6 | Immune Cell Infiltration Analysis. (A) The Lollipop Chart shows the correlation between P4HA3 expression level and 24 different immune cell-types; (B–I) the enrichment scores of P4HA3 expression for 8 immune cell-types. Abbreviations: NK, natural killer; IDC, immature dendritic cells; Tcm, effective memory T cells; Th1, T-helper 1, DC, dendritic cells.
DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

XN, SZ, and HQ contributed to conception and design of the study. XN, LR, and SW organized the database and performed the statistical analysis. XN, LR, and SW wrote the first draft of the manuscript. DG, MM, and AH wrote sections of the manuscript. SZ and HQ contributed to manuscript revision. All authors read and approved the submitted version.

FUNDING

The present work was funded by the Construction Project of Provincial Clinical Key Subject from the Health Commission of Qinghai Province.

ACKNOWLEDGMENTS

We would like to thank TCGA and GEO databases for providing platforms and contributors for uploading their meaningful data sets. The authors thank Xiantao Academic for their contribution in data analyzing and data visualizing. The present study proposal was reviewed by an institutional board, Ethics Committee of Qinghai Province Hospital of Traditional Chinese Medicine, and that the need for ethics approval had been waived.
REFERENCES

Atkinson, A., Renziehausen, A., Wang, H., Lo Nigro, C., Lattanzio, L., Merlano, M., et al. (2019). Collagen Prolyl Hydroxylases Are Bi-functional Growth Regulators in Melanoma. J. Investigative Dermatology 139, 1118–1126. doi:10.1016/j.jid.2018.10.038

Bi, J., Cheng, C., Zheng, C., Huang, C., Zheng, X., Wan, X., et al. (2021). TIPE2 Is a Checkpoint of Natural Killer Cell Maturation and Antitumor Immunity. Sci. Adv. 7, eabf6515. doi:10.1126/sciadv.abf6515

Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Gambardella, V., Castillo, J., Tarazona, N., Gimeno-Valiente, F., Martínez-Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., and Kroemer, G. (2020). Immunostimulation with Chemotherapy in the Era of Immune Checkpoint Inhibitors. Nat. Rev. Clin. Oncol. 17, 725–741. doi:10.1038/s41571-020-0413-z

Gambardella, V., Castillo, A., Tarazona, N., Gimeno-Valiente, F., Martínez-Galluzzi, L., Buqué, A., Zitvogel, L., and Kroemer, G. (2020). The Role of Tumor-Associated Macrophages in Gastric Cancer Development and Their Potential as a Therapeutic Target. Cancer Treat. Rev. 86, 102015. doi:10.1016/j.ctrv.2020.102015

Gilkes, D. M., Chaturvedi, P., Bajpai, S., Wong, C. C., Wei, H., Pitcairn, S., et al. (2015). A Novel Akt Pathway. Suppress the Growth and Metastasis of Pituitary Adenoma via Blocking PI3K-Akt Pathway. Aging 7, e11535-20191230-00598

Luo, Y., Xu, W., Chen, H., Warburton, D., Dong, R., Qian, B., et al. (2015). A Novel Pro-fibrotic Mechanism Mediated by TGFβ-Stimulated Collagen Prolyl Hydroxylase Expression in Fibrotic Lung Mesenchymal Cells. J. Pathol. 236, 384–394. doi:10.1002/path.4530

Niu, X., Ren, L., Hu, A., Zhang, S., and Qi, H. (2022). Identification of Potential Diagnostic and Prognostic Biomarkers for Gastric Cancer Based on Bioinformatic Analysis. Front. Genet. 13, 862105. doi:10.3389/fgene.2022.862105

Song, H., Liu, L., Song, Z., Ren, Y., Li, C., and Hua, J. (2018). P4HA3is Epigenetically Activated by Slg in Gastric Cancer and its Deregulation Is Associated with Enhanced Metastasis and Poor Survival. Technol. Cancer Res. Treat. 17, 153303381879648. doi:10.1177/1533033818796485

Shi, R., Gao, S., Zhang, J., Xu, J., Graham, L. M., Yang, X., et al. (2021). Collagen Prolyl 4-hydroxylases Modify Tumor Progression. Acta Biochim. Biophys. Sin. (Shanghai). 53, 805–814. doi:10.1093/abbs/gmaa065

Shoulders, M. D., and Raines, R. T. (2009). Collagen Structure and Stability. Annu. Rev. Biochem. 78, 929–958. doi:10.1146/annurev.biochem.77.033207.120833

REFERENCES